EWM
NBIX icon

Executive Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Executive Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6
Closed – – 896
2018
Q4 		$0 Buy
+6
New +$575 ﹤0.01% 899

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Executive Wealth Management's NBIX Position: Q1 2019 in Review

Executive Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 6 shares.

Executive Wealth Management first reported a position in NBIX in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • Executive Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
  • Executive Wealth Management sold 6 Neurocrine Biosciences shares in Q1 2019.
  • Executive Wealth Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 1 quarter.
  • Executive Wealth Management's Neurocrine Biosciences position peaked at $0 in Q4 2018.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on Executive Wealth Management's 13F filing for Q1 2019, filed 2 May 2019.